AZD9056 (hydrochloride)
AZD9056 hydrochloride is a selective orally active inhibitor of P2X7 which plays a significant role in inflammation and pain-causing diseases.
Product Specifications
CAS Number
345303-91-5
UNSPSC
12352005
Hazard Statement
H302, H317, H361, H373
Target
P2X Receptor
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/AZD9056-hydrochloride.html
Purity
98.18
Solubility
DMSO : 50 mg/mL (ultrasonic) |H2O : 1.67 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(C1=CC(CCCNCCCO)=CC=C1Cl)NCC2(C[C@H](C3)C4)C[C@H]4C[C@H]3C2.Cl
Molecular Formula
C24H36Cl2N2O2
Molecular Weight
455.46
Precautions
H302, H317, H361, H373
References & Citations
[1]Seeland S, et al. ATP-induced cellular stress and mitochondrial toxicity in cells expressing purinergic P2X7 receptor. Pharmacol Res Perspect. 2015 Mar;3 (2) :e00123.|[2]Elsby R, et al. In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate. Eur J Pharm Sci. 2011 May 18;43 (1-2) :41-9.|[3]Hu H, et al. Blocking of the P2X7 receptor inhibits the activation of the MMP-13 and NF-κB pathways in the cartilage tissue of rats with osteoarthritis. Int J Mol Med. 2016 Dec;38 (6) :1922-1932.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
P2X7 Receptor
Citation 01
ACS Appl Mater Interfaces. 2025 Feb 5;17 (5) :7521-7538.|Adv Sci (Weinh) . 2025 Nov 6:e14842.|Biochim Biophys Acta Mol Basis Dis. 2024 Jan;1870 (1) :166895.|Front Immunol. 2021 Jan 8;11:602016.|J Pharmacol Sci. 2020 Sep;144 (1) :43-51.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
